Dr Lal Path Labs shares soared to a new 52-week high of Rs 1,895 apiece on Monday, marking an increase of over 12% in just two sessions. This surge follows the company's announcement of a 28% year-on-year rise in consolidated net profit for Q1 FY27, reaching Rs 169.5 crore.
The company's revenue from operations also saw a significant increase, rising over 19% year-on-year to Rs 797.7 crore for the April-June quarter. Alongside these results, Dr Lal Path Labs declared an interim dividend of Rs 5 per equity share for FY27, with July 30 set as the record date for shareholder eligibility.
Nomura has maintained its 'Buy' call on Dr Lal Path Labs, raising its target price to Rs 2,085 per share from Rs 1,860. The brokerage highlighted that the company's Q1 earnings exceeded expectations, driven by higher realisations and price hikes in the CGHS and ECHS schemes. Nomura anticipates continued benefits from these price adjustments over the next 2–3 quarters.
“We believe Dr Lal Path Labs' valuation is underpinned by strong volume growth and a robust balance sheet that supports its acquisition ambitions.”
Nomura
Nuvama also noted the company's robust growth trajectory, citing network expansion and price hike-led growth as key factors. The brokerage increased its target price to Rs 2,140 per share, maintaining a 'Buy' rating. JM Financial echoed this sentiment, raising its target price to Rs 2,195 per share, supported by Dr Lal's market leadership and strong cash generation.
The positive outlook from these brokerages is underpinned by Dr Lal Path Labs' strategic focus on network expansion, high-end tests, and international market opportunities. The company plans to add 12–15 labs and 2–4 radiology centres in FY27, further bolstering its growth prospects.
Background
Dr Lal Path Labs has been a significant player in the diagnostic services sector, known for its extensive network and comprehensive test offerings. The company's strategic initiatives and market positioning have consistently driven its growth, making it a preferred choice for investors.
Looking ahead, Dr Lal Path Labs is expected to continue its growth trajectory, with analysts closely monitoring its expansion efforts and market performance. Investors will be keen to see how the company's strategies unfold in the coming quarters.
